Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention

Circulation Journal

Volumn 76, Issue 2, 2012, Pages 423-429

  Domei, Takenori ^a   Yokoi, Hiroyoshi ^a   Kuramitsu, Shoichi ^a   Soga, Yoshimitsu ^a   Arita, Takeshi ^a   Ando, Kenji ^a   Shirai, Shinichi ^a   Kondo, Katsuhiro ^a   Sakai, Koyu ^a   Goya, Masahiko ^a   Iwabuchi, Masashi ^a   Ueeda, Masayuki ^b   Nobuyoshi, Masakiyo ^a  

^a KOKURA MEMORIAL HOSPITAL   (Japan)

^b Mitoyo General Hospital   (Japan)

Author keywords

Major adverse cardiac events; Percutaneous coronary intervention; Serum EPA AA ratio

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYUNSATURATED FATTY ACID;

ACUTE CORONARY SYNDROME; AGED; ANGINA PECTORIS; ARTERY LESION; ARTICLE; CAPILLARY GAS CHROMATOGRAPHY; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; ARACHIDONIC ACID; BIOLOGICAL MARKERS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84856249003     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0941     Document Type: Article

References (37)

1. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287: 1815-1821.
2. Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006; 113: 195-202.
3. Mozaffarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: The Cardiovascular Health Study. Circulation 2003; 107: 1372-1377.
4. Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, et al. Lack of benefit of dietary advice to men with angina: Results of a controlled trial. Eur J Clin Nutr 2003; 57: 193-200.
5. GISSI-Prevenzione Investigators. Dietary supplementation with n3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-455.
6. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised openlabel, blinded endpoint analysis. Lancet 2007; 369: 1090-1098.
7. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 2009; 73: 1283-1290.
8. Hulbert AJ, Turner N, Storlien LH, Else PL. Dietary fats and membrane function: Implications for metabolism and disease. Biol Rev Camb Philos Soc 2005; 80: 155-169.
9. von Schacky C. Prophylaxis of atherosclerosis with marine omega-3 fatty acids: A comprehensive strategy. Ann Intern Med 1987; 107: 890-899.
10. Calder PC. n3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006; 83(6 Suppl): 1505S-1519S.
11. Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: A new pharmacologic genus. Br J Pharmacol 2008; 153 (Suppl 1): S200-S215.
12. Wang D, Hirase T, Nitto T, Soma M, Node K. Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor gamma in endothelial cells. J Cardiol 2009; 54: 368-374.
13. Ueeda M, Doumei T, Takaya Y, Ohnishi N, Takaishi A, Hirohata S, et al. Association of serum levels of arachidonic acid and eicosapentaenoic acid with prevalence of major adverse cardiac events after acute myocardial infarction. Heart Vessels 2011; 26: 145-152.
14. Lee SH, Shin MJ, Kim JS, Ko YG, Kang SM, Choi D, et al. Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction: Data from Infarction Prognosis Study (IPS) Registry. Circ J 2009; 73: 2250-2257.
15. Ueeda M, Doumei T, Takaya Y, Shinohata R, Katayama Y, Ohnishi N, et al. Serum N3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. Circ J 2008; 72: 1836-1843.
16. Kashiyama T, Ueda Y, Nemoto T, Wada M, Masumura Y, Matsuo K. Relationship between coronary plaque vulnerability and serum n-3/ n-6 polyunsaturated fatty acid ratio. Circ J 2011; 75: 2432-2438.
17. Nozaki S, Matsuzawa Y, Hirano K, Sakai N, Kubo M, Tarui S. Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia. Int J Vitam Nutr Res 1992; 62: 256-260.
18. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999; 10: 2177-2184.
19. Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPS-induced TNF-α expression by preventing NF-κβ activation. J Am Coll Nutr 2004; 23: 71-78.
20. Satoh N, Shimatsu A, Kotani K, Sakane N, Yamada K, Suganami T, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007; 30: 144-146.
21. Tamura Y, Hirai A, Terano T, Takenaga M, Saitoh H, Tahara K, et al. Clinical and epidemiological studies of eicosapentaenoic acid (EPA) in Japan. Prog Lipid Res 1986; 25: 461-466.
22. Kramer HJ, Stevens J, Grimminger F, Seeger W. Fish oil fatty acids and human platelets: Dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol 1996; 52: 1211-1217.
23. Gao JY, Yasuda S, Tsuburaya R, Ito Y, Shiroto T, Hao K, et al. Longterm treatment with eicosapentaenoic acid ameliorates myocardial ischemia-reperfusion injury in pigs in vivo. Circ J 2011; 75: 1843-1851.
24. Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H. Triene prostaglandins: Prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci USA 1979; 76: 944-948.
25. Terano T, Hirai A, Hamazaki T, Kobayashi S, Fujita T, Tamura Y, et al. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983; 46: 321-331.
26. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. Lancet 2003; 361: 477-485.
27. Kawano H, Yano T, Mizuguchi K, Mochizuki H, Saito Y. Changes in aspects such as the collagenous fiber density and foam cell size of atherosclerotic lesions composed of foam cells, smooth muscle cells and fibrous components in rabbits caused by all-cis-5, 8, 11, 14, 17- icosapentaenoic acid. J Atheroscler Thromb 2002; 9: 170-177.
28. Mames MJ, Gibson RA. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71: 343-348.
29. Blok WL, Katan MB, van der Meer JW. Modulation of inflammation and cytokine production by (n3) fatty acids. J Nutr 1996; 126: 1515-1533.
30. Lands WE. Diets could prevent many diseases. Lipids 2003; 38: 317-321.
31. Rapp JH, Connor WE, Lin DS, Porter JM. Dietary EPA and DHA from fish oil: Their incorporation into advanced atherosclerotic plaques. Arterioscler Thromb 1991; 11: 903-911.
32. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, et al. Eicosapentaenoic acid (EPA) from highly concentrated n3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010; 212: 252-259.
33. Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb 2011; 18: 99-107.
34. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200: 135-140.
35. Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa H, Oikawa S, et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ J 2010; 74: 1451-1457.
36. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
37. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, et al. Beyond restenosis: Five-year clinical outcomes from secondgeneration coronary stent trials. Circulation 2004; 110: 1226-1230.